NA
Therapeutic Areas
Moderna Pipeline
| Drug | Indication | Phase |
|---|---|---|
| mRNA-1345 | Respiratory Syncytial Virus (RSV) in adults ≥60 | Approved |
| mRNA-1083 | Combined Influenza + COVID-19 booster | Phase 3 |
| mRNA-1010/1011 | Seasonal Influenza | Phase 3 |
| mRNA-1647 & mRNA-1230 | Cytomegalovirus (CMV) prevention | Phase 3 |
| mRNA-4157 (V940) / KEYTRUDA® | Adjuvant treatment for high-risk melanoma (post-resection) | Approved |
| mRNA-6231 (AZURE™) | Autoimmune disorders (e.g., Systemic Lupus Erythematosus) | Phase 2 |
| mRNA-3927 | Propionic Acidemia (PA) | Phase 1/2 |
Leadership Team at Moderna
SB
Stéphane Bancel
Chief Executive Officer
SH
Stephen Hoge, M.D.
President
PB
Paul Burton, M.D., Ph.D.
Chief Medical Officer
JG
Jorge Gomez
Chief Financial Officer
AG
Arpa Garay
Chief Commercial Officer
JA
Juan Andres
President of Strategic Partnerships and Enterprise Expansion